Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 196.75M P/E - EPS this Y - Ern Qtrly Grth -
Income -74.66M Forward P/E -4.33 EPS next Y - 50D Avg Chg 11.00%
Sales 106.34M PEG - EPS past 5Y - 200D Avg Chg 38.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -5.00%
Recommedations 2.00 Quick Ratio 1.23 Shares Outstanding 382.46M 52W Low Chg 173.00%
Insider Own 0.69% ROA -11.05% Shares Float 50.24M Beta 1.64
Inst Own 53.97% ROE -37.99% Shares Shorted/Prior 10.23M/7.92M Price 2.51
Gross Margin 47.44% Profit Margin -70.21% Avg. Volume 282,504 Target Price 0.50
Oper. Margin -29.42% Earnings Date May 7 Volume 125,606 Change 0.00%
About Standard BioTools Inc.

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Standard BioTools Inc. News
04/16/24 Standard BioTools Inc. (NASDAQ:LAB): Are Analysts Optimistic?
04/08/24 Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging
04/03/24 Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research
04/02/24 Is Now The Time To Look At Buying Standard BioTools Inc. (NASDAQ:LAB)?
03/19/24 Estimating The Fair Value Of Standard BioTools Inc. (NASDAQ:LAB)
03/18/24 Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock
03/05/24 Standard BioTools Inc. (NASDAQ:LAB) Q4 2023 Earnings Call Transcript
03/01/24 Standard BioTools Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
02/29/24 Q4 2023 Standard BioTools Inc Earnings Call
02/28/24 Standard BioTools Inc (LAB) Reports Growth and Margin Expansion in FY2023 Despite Economic ...
02/28/24 Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results
02/26/24 Standard BioTools and Next Gen Diagnostics Announce Partnership to Provide Complete Automation of Low-Cost Pathogen Sequencing
02/22/24 Standard BioTools to Participate in Upcoming Investor Conferences
02/18/24 Strong week for Standard BioTools (NASDAQ:LAB) shareholders doesn't alleviate pain of five-year loss
02/14/24 Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
02/07/24 Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine
01/08/24 Insider Buyers Lose US$33k As Standard BioTools Sheds US$27m
01/08/24 Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue
01/05/24 Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools
01/04/24 Standard BioTools Stockholders Approve Merger with SomaLogic
LAB Chatroom

User Image GreenPond Posted - 1 day ago

$LAB 4/25/2024, "The unveiling ceremony of the first certified laboratory in China for Standard BioTools & SomaLogic, along with the first Proteomics and Precision Medicine Summit Forum" in Shanghai China. " Now, Yunzhun Technology has established the SomaScan® Proteomics Detection Technology Service Platform, which will provide domestic users with high-throughput proteomics detection services, further assisting domestic users in understanding health and disease biology, identifying drug targets, and developing biomarkers."

User Image jimbecker Posted - 2 days ago

$LAB Just lost the 50 day

User Image Bigbut Posted - 3 days ago

$LAB I’m on the bid

User Image GreenPond Posted - 3 days ago

$LAB Another great news today, attentions/interests from more and more analysts, next update from KeyBanc Capital Markets? Good news one followed another, yet the share price still gets stuck under $3. Shorts are brutal and aggressive, management team really needs to come up with an effective strategy to squeeze them out and scare them away!

User Image WHO905 Posted - 3 days ago

$LAB Finally worth more than PACB. I've been waiting 5 years!

User Image DonCorleone77 Posted - 4 days ago

$LAB TD Cowen starts Standard BioTools at Buy, sees 'a lot to like' TD Cowen initiated coverage of Standard BioTools with a Buy rating and $3.50 price target. The analyst sees "a lot to like" about the company's new management and strategy. The firm sees positive cash flow for the company in 2026 and 7% adjusted EBITDA margin, supported by SomaLogic cost synergies. It believes the SomaLogic merger will nearly double Standard BioTools' revenue base and bolster its overall growth outlook. TD estimates SomaLogic can grow over 20% over year beyond 2024.

User Image hermitkatt Posted - 1 week ago

$LAB nice move,loaded here

User Image GreenPond Posted - 1 week ago

$LAB "Multiplexed imaging just got a whole lot better... easier... faster..." BTW, I like the music very much, very encouraging and inspiring! https://www.youtube.com/watch?v=xwcJZQWRMhc

User Image GreenPond Posted - 1 week ago

$LAB Awesome! "We are excited to introduce the 31-plex Human #ImmunoOncology IMC™ Panel that combines tissue architecture, cell interaction and single-cell phenotypic and functional markers with the single largest Imaging Mass Cytometry™ panel currently available: " https://twitter.com/Standard_BioT/status/1778453023293120728

User Image GreenPond Posted - 1 week ago

$LAB It seems that Agilent also has been collaborating with Standard Biotools using SomaScan platform. "Agilent will also host two joint events with key collaborators. The first with SomaLogic®, now part of StandardBioTools™ on Sunday, April 7 at 1:30 pm. The focus of this symposium is cancer understanding and care. Presenters Marc Gunter from Imperial College London and Karl Smith-Byrne from Oxford University will discuss their utilization of SomaLogic’s SomaScan® Platform. They will delve into discovering novel causes and biomarkers of cancer within a large-scale prospective cohort." https://www.agilent.com/about/newsroom/presrel/2024/03apr-ca24008.html

User Image Turkeycock Posted - 1 week ago

$LLAP $LAB, been a couple good picks

User Image Turkeycock Posted - 1 week ago

$LAB nice trend

User Image Stock_Titan Posted - 1 week ago

$LAB Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging https://www.stocktitan.net/news/LAB/standard-bio-tools-introduces-new-high-throughput-multiplexed-whole-xet69orb66rf.html

User Image RockLangston Posted - 1 week ago

$ABUS $LAB $OCGN

User Image GreenPond Posted - 1 week ago

$LAB "Unlock new views in spatial biology with three new modes - Check out the imaging modes for Hyperion XTi™ for rapid whole-slide tissue imaging to get the most information from samples." https://www.youtube.com/watch?v=35xb7Yq1wzE

User Image GreenPond Posted - 1 week ago

$LAB "Just how much can you do with the new Biomark X9™ System? From 100s of NGS libraries to 1,000s of PCR reactions, here's Biomark X9 by the numbers. What can one system really do? It turns out quite a lot. The Biomark X9 System is the only genomics system that can perform real-time PCR and NGS library preparation to support discovery through screening. Now you can manage your lab’s resources, time and effort and also keep up with high-productivity demands. Watch this video to see how to streamline your real-time PCR workflows to generate up to 46,080 datapoints per 8-hour shift or produce up to 384 barcoded libraries per day for your NGS needs on one compact platform. " https://www.youtube.com/watch?v=FSzbanODoNM

User Image GreenPond Posted - 2 weeks ago

$LAB 7.4M shares traded today

User Image GreenPond Posted - 2 weeks ago

$LAB UIUC "Standard BioTools Inc. Low Bidder on Standard BioTools Consumables (Chips) *AWARDED* in Illinois Standard BioTools Inc. is the apparent low bidder on the University of Illinois Urbana-Champaign's Standard BioTools Consumables (Chips) *AWARDED* solicitation, with a low bid of $1,200,000.00 USD. Bids were opened on March 13, 2024 The contract will be for Standard BioTools Consumables (Chips)" https://www.illinoisbids.com/bid-result/standard_biotools_consumables__chips___awarded_-13267180

User Image DonCorleone77 Posted - 2 weeks ago

$LAB Standard BioTools initiated with a Buy at Jefferies Jefferies initiated coverage of Standard BioTools with a Buy rating and $3.25 price target. The analyst says the company's refreshed focus on building a platform of differentiated tech for scale and profitability is underappreciated. The firm scopes for a multiple to re-rate as management executes and visibility around the mid-term profit picture becomes more tangible.

User Image r9in Posted - 2 weeks ago

@r9in We alerted $ONMD $MOVE $LAB $ASXC and many more for FREE (temporary) Link in the description

User Image premarketmaker Posted - 2 weeks ago

$LAB this chart is performing we have been above the 30EMA for several weeks and tonight made news highs - after hours @ $3.41 (new upper line) earnings 5/7 partnership with Bristol is amazing news! stay the course - all is good management is working hard

User Image GreenPond Posted - 2 weeks ago

$LAB Great News! Do you know that SomaLogic also have a multi-year research agreement with Novartis? https://salestechstar.com/price-optimization-revenue-management/somalogic-announces-preliminary-full-year-2022-revenue-and-provides-organizational-and-strategic-updates/ "Recent extension of the contract between Novartis and SomaLogic for the use of the SomaScan Assay and Platform, with SomaLogic remaining Novartis’ primary proteomics platform through 2033. Under this long-standing agreement, SomaLogic has run over 150,000 samples for Novartis to-date (2019 to 2022), delivering high quality proteomics data to support their translational research. Recent right-size of organization to focus on greatest long-term growth"

User Image WHO905 Posted - 2 weeks ago

$LAB Tip of the iceberg! https://finance.yahoo.com/news/standard-biotools-announces-multi-strategic-200100679.html

User Image Jkpga Posted - 2 weeks ago

$LAB 🔥🔥

User Image Peak_Big Posted - 2 weeks ago

$LAB heavily shorted should be a nice squeeze tomorrow

User Image moneytawks Posted - 2 weeks ago

$LAB taking some of this crazy dip on excellent news. tight mental stop, can't trust any of these shit tickers

User Image premarketmaker Posted - 2 weeks ago

$BMY $LAB AI

User Image premarketmaker Posted - 2 weeks ago

$BMY $LAB $3.41

User Image premarketmaker Posted - 2 weeks ago

$LAB contracts with $BMY - Bristol Meyers Multi Year Contracts

User Image Turkeycock Posted - 2 weeks ago

$LAB WOW, this one too

Analyst Ratings
TD Cowen Buy Apr 16, 24
Jefferies Buy Apr 4, 24
Keybanc Overweight Jul 12, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Black Jeffrey G. SVP & Chief Financia.. SVP & Chief Financial Officer May 18 Buy 2.25 85,984 193,464 85,984 05/22/23
Casdin Eli Director Director May 17 Buy 2.11 1,200,000 2,532,000 1,200,000 05/19/23
Casdin Partners Master Fund, L... Director Director May 17 Buy 2.11 1,200,000 2,532,000 1,200,000 05/19/23
Caligan Partners LP 10% Owner 10% Owner Aug 03 Buy 1.75 301,182 527,068 11,444,836 08/05/22
Caligan Partners LP 10% Owner 10% Owner Jul 29 Buy 1.51 620,466 936,904 11,143,654 08/02/22
Caligan Partners LP - - Jun 13 Buy 1.70 100,000 170,000 10,523,188 06/15/22
Caligan Partners LP 10% Owner 10% Owner Jun 02 Buy 1.95 450,000 877,500 10,423,188 06/06/22
Caligan Partners LP 10% Owner 10% Owner May 06 Buy 2.71 488,350 1,323,428 9,973,188 05/10/22
Caligan Partners LP 10% Owner 10% Owner Apr 28 Buy 2.62 400,000 1,048,000 9,484,838 05/02/22
Caligan Partners LP 10% Owner 10% Owner Apr 06 Buy 3.75 509,573 1,910,899 8,889,838 04/08/22
BARTHELEMY NICOLAS Director Director Mar 31 Option 3.43 5,000 17,150 183,084 04/01/22
Linthwaite Stephen Christopher President & CEO President & CEO Nov 24 Option 0 19,445 239,958 11/24/20
Linthwaite Stephen Christopher President & CEO President & CEO Nov 24 Sell 6.06 84,820 514,009 145,347 11/24/20